MedPath

Spine BioPharma's SB-01 Fails to Meet Primary Endpoint in Phase 3 Trial for Chronic Low Back Pain

2 months ago4 min read

Key Insights

  • Spine BioPharma's Phase 3 MODEL trial evaluating SB-01, a TGF-β antagonist for chronic low back pain associated with degenerative disc disease, failed to meet its primary endpoint despite showing clinically meaningful improvements.

  • The 417-patient randomized controlled trial achieved a 67% success rate with SB-01 at Month 6, but this did not reach statistical significance compared to sham control due to unexpectedly high placebo response rates.

  • In sites with anticipated sham control responses, SB-01 nearly achieved statistical significance (p=0.051), suggesting the treatment may be effective when placebo effects are controlled.

Spine BioPharma announced that its Phase 3 MODEL trial evaluating SB-01, a TGF-β antagonist for intradiscal treatment of chronic low back pain associated with degenerative disc disease, failed to meet its primary endpoint of pain intensity and pain-related function at Month 6 compared to sham control. Despite the statistical miss, the treatment demonstrated clinically meaningful improvements and maintained a robust safety profile consistent with earlier studies.

Trial Design and Patient Population

The prospective, randomized, double-blind trial enrolled 417 patients across 30 sites in the United States, utilizing a 1:1 randomization to receive either a single 1.5 ml intradiscal injection of SB-01 or sham control. Both 1- and 2-level degenerative disc disease patients were included, with follow-up assessments conducted at Week 2, Week 6, Month 3, Month 6, and Month 12.
The primary endpoint required patients to achieve both a 2/10-point improvement in Numerical Rating Scale (NRS) for pain intensity and a 15/100-point improvement in Oswestry Disability Index (ODI) for pain-related function to be considered an overall composite success.

Clinical Outcomes and Safety Profile

In the Intent-to-Treat analysis of 417 patients, the SB-01 group achieved primary endpoint success of 67% at Month 6, which, although clinically meaningful, did not reach statistical significance compared to the sham control group. The treatment response was present at early timepoints and proved durable, with 62% of the SB-01 group achieving composite success at Month 12 among the 281 patients who reached that follow-up.
For the secondary endpoint of pain-related function (ODI), the SB-01 group achieved a clinically meaningful success rate of 75% at Month 6 and 71% at Month 12, but these results were not statistically significant compared to sham control. Notably, there was no difference in SB-01 success rates between 1- and 2-level patients at any timepoint.
As observed in the previous Phase 2 clinical trial of 325 patients, SB-01 demonstrated a robust safety profile throughout the Phase 3 study.

Sham Control Response Variability

A key finding was the inconsistent sham control response among sites, with some locations demonstrating much higher than anticipated placebo response rates. Fran Magee, DVM, CTO, stated, "The SB-01 patients responded as anticipated and consistent with the Phase 2 study. In contrast, the sham control response was statistically significantly higher than observed in the Phase 2 study."
The company identified statistically reliable evidence of site-to-site heterogeneity in the sham control response, while the SB-01 response remained homogenous across sites. In a subset analysis of 227 patients at sites with anticipated sham response rates consistent with the Phase 2 study, SB-01 demonstrated superior performance with a composite primary endpoint response of 70% versus 59% for sham control (nominal p=0.051). For the secondary ODI endpoint in this subset, SB-01 achieved 79% success compared to 69% for sham control (nominal p=0.040).

Clinical Significance and Next Steps

Christopher Gilligan, MD, Principal Investigator of the MODEL trial, noted, "This was a landmark, well-designed clinical trial with strict enrollment criteria and very high follow-up rates. The study employed a rigorous composite endpoint requiring patients to achieve both clinically meaningful improvement in both pain intensity and pain-related function."
Marc Viscogliosi, CEO, commented, "Despite our disappointment in missing the primary endpoint, we are quite proud of enrolling and completing this trial under strict FDA guidelines. We ran a solid trial and had we achieved our anticipated sham control group response, the results would have been statistically significant in favor of SB-01."
The company plans to complete data analysis and meet with the FDA to discuss the Phase 3 results alongside earlier Phase 1 and 2 randomized trials to explore potential approval pathways for SB-01 as a treatment for chronic low back pain associated with moderate-severe degenerative disc disease.

About SB-01 Mechanism of Action

SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokine that, when present in high concentrations in disease states, can result in negative downstream effects including inflammation, fibrosis, neoinnervation, hyperexcitability of nerves, and cell proliferation. SB-01 modulates TGF-Beta concentration without eliminating it, thereby mitigating these negative downstream effects.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Clinical Trials

Related research and studies

Highlighted Clinical Trials

NCT05516992Active, Not RecruitingPhase 3
Spine BioPharma, Inc
Posted 8/19/2022

Sources

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.